Associated Papers
IGSF10 is a RET antagonist regulating Ewing sarcoma growth and GnRH neuron migration.
Jayabal P et al.
Cell Reports, 2025
Rare genetic variation in fibronectin 1 (FN1) protects against APOEε4 in Alzheimer's disease.
Bhattarai P et al.
Acta Neuropathologica, 2024
38598053 (PubMed )
Supplement: 401_2024_2721_MOESM5_ESM.xlsx › S_Table_2
Genetic Evaluation of Patients With Delayed Puberty and Congenital Hypogonadotropic Hypogonadism: Is it Worthy of Consideration?
Festa A et al.
Frontiers in Endocrinology, 2020
SEMA3A and IGSF10 Are Novel Contributors to Combined Pituitary Hormone Deficiency (CPHD).
Budny B et al.
Frontiers in Endocrinology, 2020
A systematic review and standardized clinical validity assessment of male infertility genes.
Oud MS et al.
Human Reproduction (oxford, England), 2019
30865283 (PubMed )
Supplement: dez022_supplementary_tables_siii_-_svi_final.xlsx › Supplementary_Table_SVI
Congenital hypogonadotropic hypogonadism and constitutional delay of growth and puberty have distinct genetic architectures.
Cassatella D et al.
European Journal of Endocrinology, 2018
IGSF10 mutations dysregulate gonadotropin-releasing hormone neuronal migration resulting in delayed puberty.
Howard SR et al.
Embo Molecular Medicine, 2016
De novo mutations in moderate or severe intellectual disability.
Hamdan FF et al.
Plos Genetics, 2014
25356899 (PubMed )
Supplement: pgen.1004772.s004.xlsx › 1861.653
Select a paper to view details